Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colchicine in NSTEMI Patients
NCT07143136Phase 1Recruiting
- Sponsor
- Assiut University
- Start
- Aug 2025
- Primary completion
- Mar 2026
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of colchicine in non-ST segment elevation myocardial infarction (NSTEMI) (2 arms), sponsored by Assiut University. Primary endpoint: Incidence of Major Adverse Cardiovascular Events at 6 months. Started Aug 2025; status: recruiting.
02
Drugs
colchicine
03
Conditions
non-ST segment elevation myocardial infarction (NSTEMI)
Beyond the preview
Go deeper on NCT07143136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07143136.